180 LIFE SCIENCES CORP (ATNF)

US68236V3024 - Common Stock

2  0 (0%)

Fundamental Rating

1

ATNF gets a fundamental rating of 1 out of 10. The analysis compared the fundamentals against 588 industry peers in the Biotechnology industry. ATNF has a bad profitability rating. Also its financial health evaluation is rather negative. ATNF is valied quite expensively at the moment, while it does show a decent growth rate.



Quickly go to:

0

1. Profitability

1.1 Basic Checks

ATNF had negative earnings in the past year.
ATNF had a negative operating cash flow in the past year.
ATNF had negative earnings in each of the past 5 years.
In the past 5 years ATNF always reported negative operating cash flow.

1.2 Ratios

With a Return On Assets value of -379.07%, ATNF is not doing good in the industry: 95.39% of the companies in the same industry are doing better.
Industry RankSector Rank
ROA -379.07%
ROE N/A
ROIC N/A
ROA(3y)-202.68%
ROA(5y)-126.08%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A

1.3 Margins

The Profit Margin and Operating Margin and Gross Margin are not available for ATNF so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A

More info and screens

0

2. Health

2.1 Basic Checks

The number of shares outstanding for ATNF has been reduced compared to 1 year ago.
The number of shares outstanding for ATNF has been increased compared to 5 years ago.
ATNF has a worse debt/assets ratio than last year.

2.2 Solvency

Based on the Altman-Z score of -42.49, we must say that ATNF is in the distress zone and has some risk of bankruptcy.
The Altman-Z score of ATNF (-42.49) is worse than 93.52% of its industry peers.
Industry RankSector Rank
Debt/Equity N/A
Debt/FCF N/A
Altman-Z -42.49
ROIC/WACCN/A
WACCN/A

2.3 Liquidity

A Current Ratio of 0.72 indicates that ATNF may have some problems paying its short term obligations.
ATNF has a Current ratio of 0.72. This is amonst the worse of the industry: ATNF underperforms 93.69% of its industry peers.
A Quick Ratio of 0.72 indicates that ATNF may have some problems paying its short term obligations.
Looking at the Quick ratio, with a value of 0.72, ATNF is doing worse than 93.00% of the companies in the same industry.
Industry RankSector Rank
Current Ratio 0.72
Quick Ratio 0.72

More info and screens

4

3. Growth

3.1 Past

ATNF shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 71.07%, which is quite impressive.
EPS 1Y (TTM)71.07%
EPS 3YN/A
EPS 5YN/A
EPS growth Q2Q79.79%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Revenue growth Q2QN/A

3.2 Future

The Earnings Per Share is expected to grow by 22.47% on average over the next years. This is a very strong growth
ATNF is expected to show a strong growth in Revenue. In the coming years, the Revenue will grow by 134.74% yearly.
EPS Next Y50%
EPS Next 2Y22.47%
EPS Next 3YN/A
EPS Next 5YN/A
Revenue Next Year481.87%
Revenue Next 2Y199.5%
Revenue Next 3Y177.22%
Revenue Next 5Y134.74%

3.3 Evolution

More info and screens

1

4. Valuation

4.1 Price/Earnings Ratio

ATNF reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Also next year ATNF is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A

4.3 Compensation for Growth

A more expensive valuation may be justified as ATNF's earnings are expected to grow with 22.47% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y22.47%
EPS Next 3YN/A

More info and screens

0

5. Dividend

5.1 Amount

ATNF does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

180 LIFE SCIENCES CORP

NASDAQ:ATNF (5/3/2024, 7:00:01 PM)

2

0 (0%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)
Earnings (Next)
Inst Owners
Inst Owner Change
Ins Owners
Ins Owner Change
Market Cap1.70M
Analysts
Price Target
Dividend
Industry RankSector Rank
Dividend Yield N/A
Dividend Growth(5Y)
DP
Div Incr Years
Div Non Decr Years
Ex-Date
Surprises & Revisions
EPS beat(2)
Avg EPS beat(2)
Min EPS beat(2)
Max EPS beat(2)
EPS beat(4)
Avg EPS beat(4)
Min EPS beat(4)
Max EPS beat(4)
EPS beat(8)
Avg EPS beat(8)
EPS beat(12)
Avg EPS beat(12)
EPS beat(16)
Avg EPS beat(16)
Revenue beat(2)
Avg Revenue beat(2)
Min Revenue beat(2)
Max Revenue beat(2)
Revenue beat(4)
Avg Revenue beat(4)
Min Revenue beat(4)
Max Revenue beat(4)
Revenue beat(8)
Avg Revenue beat(8)
Revenue beat(12)
Avg Revenue beat(12)
Revenue beat(16)
Avg Revenue beat(16)
PT rev (1m)
PT rev (3m)
EPS NQ rev (1m)
EPS NQ rev (3m)
EPS NY rev (1m)
EPS NY rev (3m)
Revenue NQ rev (1m)
Revenue NQ rev (3m)
Revenue NY rev (1m)
Revenue NY rev (3m)
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S
P/FCF
P/OCF
P/B
P/tB
EV/EBITDA
EPS(TTM)
EY
EPS(NY)
Fwd EY
FCF(TTM)
FCFY
OCF(TTM)
OCFY
SpS
BVpS
TBVpS
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -379.07%
ROE N/A
ROCE
ROIC
ROICexc
ROICexgc
OM N/A
PM (TTM) N/A
GM N/A
FCFM
ROA(3y)
ROA(5y)
ROE(3y)
ROE(5y)
ROIC(3y)
ROIC(5y)
ROICexc(3y)
ROICexc(5y)
ROICexgc(3y)
ROICexgc(5y)
ROCE(3y)
ROCE(5y)
ROICexcg growth 3Y
ROICexcg growth 5Y
ROICexc growth 3Y
ROICexc growth 5Y
OM growth 3Y
OM growth 5Y
PM growth 3Y
PM growth 5Y
GM growth 3Y
GM growth 5Y
F-Score
Asset Turnover0
Health
Industry RankSector Rank
Debt/Equity N/A
Debt/FCF
Debt/EBITDA
Cap/Depr
Cap/Sales
Interest Coverage
Cash Conversion
Profit Quality
Current Ratio 0.72
Quick Ratio 0.72
Altman-Z
F-Score
WACC
ROIC/WACC
Cap/Depr(3y)
Cap/Depr(5y)
Cap/Sales(3y)
Cap/Sales(5y)
Profit Quality(3y)
Profit Quality(5y)
Growth
EPS 1Y (TTM)71.07%
EPS 3YN/A
EPS 5Y
EPS growth Q2Q
EPS Next Y50%
EPS Next 2Y
EPS Next 3Y
EPS Next 5Y
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5Y
Revenue growth Q2Q
Revenue Next Year
Revenue Next 2Y
Revenue Next 3Y
Revenue Next 5Y
EBIT growth 1Y
EBIT growth 3Y
EBIT growth 5Y
EBIT Next Year
EBIT Next 3Y
EBIT Next 5Y
FCF growth 1Y
FCF growth 3Y
FCF growth 5Y
OCF growth 1Y
OCF growth 3Y
OCF growth 5Y